Thermo Fisher Scientific Phospho-ELK1 (Ser389) Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 1:500–1:1,000
• Suggested Positive Control: HT29 cells

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 1:50–1:100
• Suggested Positive Control: Human breast carcinoma

Product Specifications

Product Specific Information

A suggested positive control for Western blot is HT29 cells; suggested positive control for IHC is human breast carcinoma.

Target Information

ELK1 is a component of the ternary complex that binds the serum response element (SRE) and mediates gene activity in response to serum and growth factors.
ELK1 is phosphorylated by MAP kinase pathways at a cluster of S/T motifs at its C-terminus. Phosphorylation at these sites, particularly Ser383, is critical for transcriptional activation by ELK1.
ELK1 appears to be a direct target of activated MAP kinase. Biochemical studies indicate that ELK1 is a good substrate for MAP kinase, the kinetics of ELK1 phosphorylation and activation correlate with MAP kinase activity, and interfering mutants of MAP kinase block ELK1 activation in vivo.
ELK1 is a nuclear target for the ras-raf-MAPK signaling cascade. Alternatively spliced transcript variants encoding the same protein have been found for ELK1.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.